Uncategorized
Epitope Editing Strategy Could Enable Less Toxic Stem Cell Transplants
Stem cell transplantation and gene therapy are among the most powerful curative approaches for blood diseases such as sickle cell disease, β-thalassemia, immune deficiencies, and some blood cancers. Replacing or correcting the blood-forming stem cells can offer the possibility of long-lasting benefit or a cure. However, before patients can receive these therapies, they usually need intensive and potentially toxic chemotherapy or radiation to clear space in the bone marrow for the new stem cells.
Researchers headed by teams at Boston Children’s Hospital and Dana-Faber Cancer Institute have developed a new strategy to make stem cell transplants safer by replacing chemotherapy-based treatment with a more targeted approach. Instead of using toxic agents that damage DNA throughout the body, the team developed an donor stem cell epitope-editing strategy and antibodies that recognize surface markers only on the blood-forming stem cells that need to be depleted. Reporting on their developments in Nature (“Non-genotoxic transplantation and in vivo selection through epitope editing,”) the team demonstrated that these antibodies can help clear the patient’s existing stem cells from the bone marrow in a more selective, less toxic way.
Hematopoietic stem/progenitor cell (HSPC) transplantation (HSCT) is a cornerstone therapy for a wide range of malignant and non-malignant conditions, “… leveraging the unique regenerative capacity of HSPCs to replenish the hematopoietic system,” the authors wrote. However, they pointed out, the short-term and long-term effects of pre-transplant genotoxic conditioning represent real barriers to broader use of HSPC transplantation and gene therapies.
Although monoclonal antibodies have been proposed as alternatives to chemotherapy or radiotherapy, they are also associated with efficacy and safety challenges, the team noted. An antibody normally cannot distinguish between the patient’s original stem cells and the infused therapeutic stem cells from the treatment. If the antibody remains in the body, it may also attack these transplanted cells, preventing them from integrating. “… immune-based agents pose efficacy and safety challenges due to nonselective targeting of transplanted HSPCs and prolonged half-life, leading to on-target depletion,” the investigators stated.
Researcher Pietro Genovese, PhD, of the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, and his team solved this problem by giving the therapeutic stem cells a form of molecular protection. Using precise genome-editing tools, they made changes to a tiny recognition site—epitope—on the surface of the donor stem cells. This small change prevented the antibody from binding to the therapeutic cells, while preserving the normal function of the protein. “… we identified amino acid changes in the extracellular domain of KIT that disrupt the binding of two therapeutic monoclonal antibodies, which impair stem cell factor (SCF)-mediated signaling without affecting KIT expression or functionality,” they explained.
The edited stem cells were in effect given a molecular camouflage. They could hide from the antibody, while the unedited cells remained vulnerable. In previous work the team had used the same general principle of epitope editing to protect healthy blood stem cells from cancer immunotherapies, such as CAR T cells or therapeutic antibodies, while allowing those therapies to attack leukemia cells.
The newly reported approach included therapeutic editing of blood stem cells to increase fetal hemoglobin (HbF), a protective form of hemoglobin that can compensate for the defective adult hemoglobin found in sickle cell disease and β-thalassemia. “In our experiments, KIT and BCL11A were efficiently co-edited in primary HSPCs, endowing their progeny with both HbF induction and mAb resistance,” the investigators commented. The results showed that the protected, epitope-edited stem cells can survive antibody treatment, integrate in the bone marrow, and enrich gradually over time. The findings point to a new way to make room for transplanted cells, and also selectively favor the therapeutic cells after transplantation.
“By avoiding chemotherapy, we can open up stem cell transplants for diseases that are less severe or for fragile patients normally too sick or too high risk for transplantation,” said first author Gabriele Casirati, MD, an instructor in Genovese’s lab. “Typically, bone marrow transplants are reserved for patients with life-threatening diseases but are simultaneously limited to those patients who can tolerate the chemotherapy.”
This work could have implications for the future of both stem cell and gene therapy. First, it may help enable chemotherapy-free or chemotherapy-sparing transplantation approaches, reducing the burden of treatment for patients who currently face the risks of DNA damage. Second, because the antibody can continue to select for protected cells after transplantation, the strategy could help therapeutic stem cells reach the levels needed for clinical benefit. “In conclusion, our findings support the paradigm-shifting potential of epitope editing to design next-generation HSCT,” the team stated.
The broader significance extends beyond inherited blood disorders. Together, these studies suggest that epitope editing could become a flexible platform: one application could make stem cell transplantation and gene therapy safer, while another could expand the use of cancer immunotherapy by protecting normal blood formation from unintended damage. “… by overcoming the limitations of monoclonal antibody pharmacokinetics, epitope editing enables novel hematopoietic replacement regimens that are not limited by on-target graft elimination, allowing prolonged immune-based conditioning that maximizes hematopoietic niche clearance without chemo-radiotherapy or monoclonal antibody wash-out,” they noted.
“Although this work is still preclinical, it points toward a future in which patients may receive curative stem cell therapies with less toxicity, less reliance on chemotherapy, and greater precision,” said Genovese. “By combining targeted biological conditioning with molecularly protected therapeutic stem cells, this strategy offers a new framework for safer and more accessible treatments for a wide range of blood diseases.”
The technology used in this study is jointly owned by Boston Children’s and Dana-Farber Cancer Institute. In their paper the team commented, “We envision a future where patients receive life-saving stem cell therapies without risks of prolonged aplasia, infertility or secondary malignancies, and with minimal or no hospitalization.”
The post Epitope Editing Strategy Could Enable Less Toxic Stem Cell Transplants appeared first on GEN – Genetic Engineering and Biotechnology News.
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized5 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
Nature Biotechnology8 months ago
Mapping cis-regulatory mutations at scale in sorghum enables modulation of gene expression
Scan to Read